MapLight Therapeutics (MPLT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.32
- Estimate
- -$1.31
- Surprise
- -1.0%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
MapLight Therapeutics (MPLT) reported a wider loss than forecast — adjusted EPS of -$1.32 against the -$1.31 estimate (a 1.0% shortfall).
Coverage in the report window
- MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate — benzinga, 2026-08-13
- MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates MPLT Sell at 4.9/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -1.0% surprise compares with a -569.2% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: ML-007C-MA (lead product candidate)
- Quality below floor (1.6 < 4.0)
- Momentum score 2.5/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.46
- Price target
- $23.09
- Stop
- $9.83
- Upside to target
- +120.7%
- Reward-to-risk
- 8.1:1
Risk check: RSI 10 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-26 — shown for context, not personalized investment advice.
MPLT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $581.3M
- P/E (fwd)
- -3.2
- 52-week range
- $9.10–$40.43
- Off 52-week high
- 74.1%
- RSI (14)
- 10
- Volume vs avg
- 0.55×
- Score today
- 4.9/10